Header cover image

Brazilian (BOVESPA) Drug Retail Industry Analysis

UpdatedJan 18, 2025
DataAggregated Company Financials
Companies4
  • 7D1.2%
  • 3M-14.4%
  • 1Y-20.6%
  • YTDn/a

Over the last 7 days, the Drug Retail industry has dropped 1.2%, driven by a pullback from Raia Drogasil of 1.4%. The industry has fallen 23% in the last year. As for the next few years, earnings are expected to grow by 20% per annum.

Industry Valuation and Performance

Has the Brazilian Drug Retail Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 18 Jan 2025R$39.2bR$56.7bR$1.4b12x27.9x0.7x
Mon, 16 Dec 2024R$43.9bR$56.7bR$1.4b12.2x31.2x0.8x
Wed, 13 Nov 2024R$47.4bR$56.6bR$1.4b13.9x34x0.8x
Fri, 11 Oct 2024R$45.6bR$54.8bR$1.3b16.5x36.4x0.8x
Sun, 08 Sep 2024R$50.7bR$54.8bR$1.3b17.6x40.5x0.9x
Tue, 06 Aug 2024R$55.0bR$53.1bR$1.2b32.3x45.5x1x
Thu, 04 Jul 2024R$47.3bR$53.1bR$1.2b28.6x39.2x0.9x
Sat, 01 Jun 2024R$46.3bR$53.1bR$1.2b27.8x38.2x0.9x
Mon, 29 Apr 2024R$47.4bR$51.4bR$1.2b29.8x40.6x0.9x
Wed, 27 Mar 2024R$50.0bR$51.4bR$1.2b31.7x42.8x1x
Fri, 23 Feb 2024R$47.8bR$49.8bR$1.1b20.1x45.2x1x
Sun, 21 Jan 2024R$50.1bR$49.8bR$1.1b20.6x47.3x1x
Tue, 19 Dec 2023R$54.6bR$49.8bR$1.1b21.2x51.6x1.1x
Thu, 16 Nov 2023R$49.4bR$49.7bR$1.0b21.4x48.7x1x
Sat, 14 Oct 2023R$51.0bR$48.1bR$948.8m20.1x53.7x1.1x
Mon, 11 Sep 2023R$49.8bR$48.1bR$948.8m21.6x52.4x1x
Wed, 09 Aug 2023R$51.7bR$46.0bR$1.1b23.2x48.7x1.1x
Fri, 07 Jul 2023R$52.1bR$46.0bR$1.1b22.8x49x1.1x
Sun, 04 Jun 2023R$50.8bR$46.0bR$1.1b20.9x47.9x1.1x
Tue, 02 May 2023R$46.3bR$43.7bR$1.1b17.9x42.4x1.1x
Thu, 30 Mar 2023R$43.2bR$43.7bR$1.1b16.5x39.5x1x
Sat, 25 Feb 2023R$41.0bR$41.4bR$1.0b30.3x40.6x1x
Mon, 23 Jan 2023R$43.3bR$41.4bR$1.0b31.4x42.8x1x
Wed, 21 Dec 2022R$42.5bR$41.4bR$1.0b31x42x1x
Fri, 18 Nov 2022R$41.7bR$41.4bR$1.0b31.1x41.3x1x
Sun, 16 Oct 2022R$41.6bR$39.2bR$1.0b21.2x39.6x1.1x
Tue, 13 Sep 2022R$42.6bR$39.2bR$1.0b20.2x40.6x1.1x
Thu, 11 Aug 2022R$41.3bR$38.9bR$1.0b34x40x1.1x
Sat, 09 Jul 2022R$36.6bR$37.4bR$945.0m32.2x38.8x1x
Mon, 06 Jun 2022R$39.7bR$37.4bR$945.0m35x42.1x1.1x
Wed, 04 May 2022R$38.3bR$36.2bR$978.0m33.4x39.2x1.1x
Fri, 01 Apr 2022R$46.0bR$36.0bR$997.8m39.2x46.1x1.3x
Sun, 27 Feb 2022R$45.3bR$35.8bR$1.0b33.2x44.6x1.3x
Tue, 25 Jan 2022R$40.0bR$34.8bR$1.0b30.5x39.7x1.1x
Price to Earnings Ratio

39.7x


Total Market Cap: R$40.0bTotal Earnings: R$1.0bTotal Revenue: R$34.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Brazilian Drug Retail Industry Price to Earnings3Y Average 42.5x202320242025
Current Industry PE
  • Investors are pessimistic on the Brazilian Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 28.8x which is lower than its 3-year average PE of 42.6x.
  • The 3-year average PS ratio of 1.0x is higher than the industry's current PS ratio of 0.72x.
Past Earnings Growth
  • The earnings for companies in the Drug Retail industry have grown 12% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Brazilian Drug Retail compare with similar industries?

BR Market2.55%
Consumer Staples-1.23%
Food and Staples Retail2.31%
Drug Retail1.20%
Big Box Super Stores3.86%
Food Distributors0%
Food Retail-2.17%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RADL3 Raia DrogasilR$21.231.2%
+R$445.9m
-21.1%PE32.8x
PGMN3 Empreendimentos Pague MenosR$3.373.4%
+R$63.2m
-2.3%PE12.1x
DMVF3 d1000 Varejo Farma ParticipaçõesR$6.039.2%
+R$25.8m
0.7%PE9.7x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.